The effects of 5% Imiquimod cream on high-grade vulval intraepithelial neoplasia

David Luesley, Richard Todd, Ian Etherington

Research output: Contribution to journalArticle

63 Citations (Scopus)


OBJECTIVES: The aim of this study was to investigate the effects of topical 5% Imiquimod (3M Pharmaceuticals, St. Paul, Minnessota) on high-grade vulval intraepithelial neoplasia (VIN). METHODS: A prospective uncontrolled observational study was performed. Fifteen patients with histologically confirmed VIN 3 were asked to self-administer 5% Imiquimod cream to their vulval lesions up to three times weekly for 16 weeks. Review was conducted at 1, 2, 3, 4, 6, and 9 months postrecruitment. Lesions were photodocumented and at 4 months any areas demonstrating a clinical response were biopsied. RESULTS: Of 15 patients recruited, 4 demonstrated a clinical improvement in their disease, 3 of whom had negative biopsies posttreatment. Local side effects limited the frequency of application such that 7 patients applied the cream once weekly, 6 twice weekly, and 2 three times weekly. CONCLUSIONS: 5% Imiquimod cream appears to have an effect when used on high-grade VIN. The frequency of application was limited by local side effects which may have reduced the clinical responses seen. Measures to alleviate local side effects may allow more aggressive use of Imiquimod and lead to improved responses.
Original languageEnglish
Pages (from-to)67-70
Number of pages4
JournalGynecologic oncology
Issue number1
Publication statusPublished - 1 Apr 2002


Dive into the research topics of 'The effects of 5% Imiquimod cream on high-grade vulval intraepithelial neoplasia'. Together they form a unique fingerprint.

Cite this